Skip to main contentWhat Are Cognitive Research Peptides?
Cognitive research peptides are synthetic compounds used as pharmacological tools to interrogate discrete signaling pathways in the central nervous system. Semax, Selank, and Dihexa represent three structurally distinct classes: an ACTH-derived heptapeptide analog, a tuftsin-derived immunomodulatory heptapeptide, and an angiotensin IV analog hexapeptide, respectively. Their research utility comes from selectivity — each compound targets a specific receptor system or signaling axis, making them useful probes for dissecting molecular mechanisms in cell culture and animal models without the broad receptor polypharmacology that characterizes many CNS-active reference compounds. Published literature characterizes each for effects on neurotrophin expression, inhibitory receptor modulation, and synaptogenic signaling — distinct enough that a lab running parallel receptor binding assays would use all three for different mechanistic questions rather than selecting one as a surrogate for the others. All three are studied for research purposes only. Onward Aminos supplies research-grade preparations intended exclusively for laboratory and preclinical investigation.
How Does Semax Modulate BDNF and Cognitive Research Models?
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone fragment ACTH(4-7), extended at the C-terminus with Pro-Gly-Pro. Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro, sometimes abbreviated MNPAF in shorthand notation. The ACTH(4-7) core is thought to interact with melanocortin receptors, with downstream BDNF induction proposed as a secondary consequence of that receptor engagement — not a direct neurotrophin agonist mechanism. Published research has characterized Semax's capacity to upregulate brain-derived neurotrophic factor (BDNF) expression in neuronal cell cultures and rodent brain tissue models, with activation of TrkB downstream of BDNF elevation. Ashmarin et al. investigated Semax-induced BDNF elevation and downstream TrkB receptor activation in neuronal preparations [PMID: 16445185]. Medvedeva et al. examined gene expression profiles following Semax exposure in brain tissue models, identifying transcriptional changes across multiple neurotrophic pathways — a broader transcriptomic effect than the BDNF axis alone [PMID: 18841466]. These findings position Semax as a research tool for studying neurotrophin regulation in neuroprotection and cognitive function models. All research applications use this compound for preclinical purposes only.
What Is the Anxiolytic Mechanism of Selank in Research?
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, C-terminally extended with Gly-Pro-Lys. Amino acid sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. Molecular formula C₄₆H₇₃N₁₃O₁₃, molecular weight 1046.2 g/mol. Selank's primary characterized mechanism is allosteric modulation of GABA-A receptors in neuronal preparations — distinct from the benzodiazepine site interaction, with different subunit selectivity and functional consequences. Kozlovskaya et al. described Selank's effects on GABA-A receptor subunit composition and chloride channel conductance in cell culture models [PMID: 22786332]. Kozlovsky et al. investigated Selank's influence on enkephalin system activity and neurotransmitter expression profiles in brain tissue preparations, characterizing interactions with opioid receptor pathways as a secondary mechanistic dimension [PMID: 22968004]. Uchakina et al. examined Selank's immunomodulatory properties, including modulation of interleukin expression in immune cell culture systems [PMID: 20717095]. In animal models, Selank has produced anxiolytic-like behavioral outcomes in elevated plus maze and open field paradigms. Selank is supplied by Onward Aminos for research purposes only.
How Does Dihexa Activate HGF/c-Met Signaling Pathways?
Dihexa (designated PNB-0408) is a synthetic hexapeptide analog of angiotensin IV, engineered for high-affinity binding at the hepatocyte growth factor (HGF) receptor complex c-Met. Its structural origin is angiotensin IV with modifications that enhance c-Met binding affinity and selectivity. The mechanism is a departure from the other two compounds in this comparison: rather than modulating inhibitory receptor systems or neurotrophic factor expression, Dihexa drives synaptogenic signaling through a receptor tyrosine kinase axis. McCoy et al. demonstrated that Dihexa binds HGF with high affinity and transactivates c-Met signaling cascades in hippocampal preparations, producing synaptogenic effects measurable in neuronal cell culture models [PMID: 23090578]. Bhatt et al. investigated the synaptogenic properties of Dihexa in rodent models, observing increases in synaptic density markers in hippocampal tissue — output from the downstream PI3K/Akt and MAPK/ERK cascades that c-Met activation engages [PMID: 23548006]. Wright et al. characterized the angiotensin IV binding site and its role in cognitive function in rodent models, establishing the foundational receptor pharmacology context for Dihexa and related analogs [PMID: 20888304]. All applications are for preclinical research only.
Comparison Table
| Compound | Origin | Mechanism | Receptor Target | Molecular Weight | Primary Research Application | Key PMIDs |
|---|---|---|---|---|---|---|
| Semax | ACTH(4-7) analog | BDNF upregulation | TrkB (indirect) | 813 Da | Neuroprotection, cognitive studies | 16445185, 18841466 |
| Selank | Tuftsin analog | GABA-A modulation, enkephalin | GABA-A, opioid receptors | 751 Da | Anxiolytic research, stress response | 22786332, 22968004, 20717095 |
| Dihexa | Angiotensin IV analog | HGF/c-Met agonism | c-Met | 811 Da | Synaptogenesis, cognitive enhancement research | 23090578, 23548006 |
What Does Published Research Show About Each Compound?
The published evidence base for each compound is focused and mechanistically distinct. For Semax: Ashmarin et al. documented BDNF induction and TrkB activation in neuronal cultures [PMID: 16445185], and Medvedeva et al. extended that picture with broader transcriptomic characterization of neurotrophic pathway responses [PMID: 18841466]. For Selank: the primary mechanistic characterization comes from Kozlovskaya et al. on GABA-A receptor allosteric modulation [PMID: 22786332] and Kozlovsky et al. on enkephalin system interactions [PMID: 22968004] — two distinct receptor-level mechanisms in a single compound, which is part of what makes Selank a useful probe for labs studying the intersection of GABAergic and opioid signaling. For Dihexa: McCoy et al. and Bhatt et al. established the HGF/c-Met transactivation mechanism and downstream synaptogenic outcomes in hippocampal models [PMID: 23090578] [PMID: 23548006], with Dihexa's high potency relative to endogenous HGF as a distinguishing feature in receptor activation assays. Across all three compounds, findings are derived from cell culture systems and rodent preclinical models. No clinical conclusions are supported by this literature in the context of research-grade compound supply. Onward Aminos provides each compound strictly for laboratory investigation.
Frequently Asked Questions
What distinguishes Semax from other ACTH-derived peptides in research?
Semax is distinguished by its specific core sequence ACTH(4-7) — Met-Glu-His-Phe — extended with a C-terminal Pro-Gly-Pro tripeptide that enhances metabolic stability and influences receptor binding kinetics. Most ACTH fragment analogs studied in published literature target melanocortin receptor subtypes and modulate stress-axis signaling primarily. Semax's differentiating property is secondary induction of BDNF and activation of TrkB-dependent neurotrophic signaling downstream of its primary receptor interaction — not a direct neurotrophin mechanism [PMID: 16445185]. That BDNF-upregulating profile is not consistently reported for other ACTH fragment analogs such as ACTH(1-24) or alpha-MSH. Medvedeva et al. further demonstrated that Semax modulates broader gene expression networks related to neuroplasticity beyond the BDNF axis alone [PMID: 18841466]. The Pro-Gly-Pro extension appears central to Semax's differentiated pharmacological profile in rodent models and neuronal cell culture systems. All Semax is supplied for research purposes only by Onward Aminos.
How is Selank's mechanism of action different from synthetic benzodiazepines in research models?
Selank and synthetic benzodiazepines both interact with GABA-A receptors, but at distinct binding sites with different functional consequences in published research models. Classical benzodiazepines engage the benzodiazepine site at the alpha/gamma subunit interface, producing positive allosteric modulation and increasing chloride conductance broadly. Selank's GABA-A receptor interaction, characterized by Kozlovskaya et al., is described as allosteric modulation with subunit selectivity that diverges from the benzodiazepine binding profile [PMID: 22786332]. Beyond that mechanistic distinction, Selank also engages enkephalin system pathways — an interaction not associated with classical benzodiazepines in published preclinical models [PMID: 22968004]. Selank additionally carries tuftsin-derived immunomodulatory properties including effects on interleukin expression characterized by Uchakina et al. [PMID: 20717095]. These distinct mechanistic features make Selank useful in research designs that require GABA-A modulation without full benzodiazepine receptor occupancy and where the immunomodulatory dimension is a variable of interest. Selank is available from Onward Aminos for research purposes only.
What is the significance of HGF/c-Met signaling in Dihexa research?
HGF/c-Met is a receptor tyrosine kinase pathway regulating neuronal survival, synaptic plasticity, and axonal growth in the central nervous system. Dihexa's significance as a research tool derives from its capacity to act as a potent HGF mimetic that transactivates c-Met receptors without requiring endogenous HGF ligand. McCoy et al. demonstrated picomolar affinity HGF binding and downstream c-Met phosphorylation in hippocampal tissue preparations [PMID: 23090578]. This receptor engagement activates PI3K/Akt and MAPK/ERK cascades, which are associated with neuronal survival signaling and dendritic spine dynamics. Bhatt et al. reported increased synaptic density markers in hippocampal preparations following Dihexa treatment in rodent models — a functional output of those downstream cascades [PMID: 23548006]. The HGF/c-Met axis is also implicated in neuroprotection following ischemic injury in preclinical models. Dihexa's reported potency exceeding that of endogenous HGF in certain activation assays is what distinguishes it as a pharmacological probe relative to native ligand-based approaches. All Dihexa uses are for preclinical research only.
How do researchers measure BDNF changes in Semax studies?
Published Semax research employs several standard measurement approaches. ELISA-based protein quantification measures BDNF concentrations in conditioned media, tissue homogenates, and cerebrospinal fluid fractions from rodent models. Quantitative PCR measures BDNF mRNA transcript levels in neuronal cell preparations and brain tissue sections, allowing comparison of transcriptional induction across treatment conditions and time points. Immunohistochemistry with anti-BDNF antibodies enables spatial localization in specific brain regions — hippocampus and cortex are the primary targets. Western blotting confirms mature BDNF protein levels alongside precursor proBDNF in tissue lysates. TrkB receptor phosphorylation assays — phospho-TrkB ELISA and co-immunoprecipitation — confirm downstream receptor activation as a functional readout of BDNF induction, as characterized in Semax treatment contexts by Ashmarin et al. [PMID: 16445185]. Medvedeva et al. applied gene expression arrays to capture broader transcriptomic responses including pathways beyond the BDNF-TrkB axis [PMID: 18841466]. All measurement approaches are applied in preclinical or in vitro contexts only.
What research models are used to study Selank's anxiolytic properties?
Published research on Selank's anxiolytic properties uses both behavioral and neurobiological readouts in rodent models. The elevated plus maze quantifies anxiolytic-like behavior by measuring time in open versus closed arms — a validated paradigm for GABA-active compounds. The open field test assesses locomotor activity and center-zone exploration, which correlate with anxiety-like states in rodent models. Published studies by Kozlovskaya et al. and Kozlovsky et al. used neurochemical endpoints — GABA-A receptor binding assays and enkephalin peptide quantification — to establish mechanistic correlates of the behavioral outcomes [PMID: 22786332] [PMID: 22968004]. Stress-induced hyperthermia models assess anxiolytic effects at the physiological level, providing a complementary readout to behavioral paradigms. In vitro models use direct receptor binding measurements in neuronal cell preparations to characterize GABA-A interaction parameters independently of behavioral complexity. Uchakina et al. used immune cell culture systems to characterize the immunomodulatory dimension, which is studied separately from the behavioral endpoint work [PMID: 20717095]. All models are preclinical; Selank is supplied by Onward Aminos for research purposes only.
All compounds listed are for research purposes only. Onward Aminos provides research-grade peptides intended for laboratory and preclinical research. Not for human or veterinary use.